Background: Aortoesophageal fistula (AEF) is an uncommon condition that presents a problem in therapy because of the high rate of morbidity and mortality associated with its surgical management and the uniformly fatal outcome of medical treatment. In this article we describe a case of secondary AEF after endoluminal stent grafting of the thoracic aorta, which was observed by only conservative management and followed up for 14 months with no signs of recurrent hemorrhage or chronic mediastinitis.
Case Report: A 54-year old man with hepatocellular carcinoma (HCC) was admitted to our hospital because of tarry stool. He had a history of traumatic aneurysm, and undergone segmental replacement with a stent graft three years ago. After admission, Esophagogastroduodenoscopy and computed tomography identified AEF. He was treated conservatively, because his stage of HCC was advanced. Oral intake was prohibited, and the patient received proton pump inhibitors, intravenous hyperalimentation and antibiotics. Afterwards, no signs of hemorrhage were observed. Although oral intake was resumed after that, another bleeding event or development of mediastinitis was not observed. Subsequently, He was received chemotherapy for advanced HCC, and we observed downstaging of his advanced HCC.
Conclusions: Although we observed 14 months survival in our case under conservative management of secondary AEF, it seems that the treatment of secondary AEF should do the operative management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539520 | PMC |
| http://dx.doi.org/10.12659/msm.881702 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aspergillus Species as a Rare Cause of Primary Mycotic Aneurysm With Aortoenteric Fistula.
Cureus
December 2024
Vascular Surgery, King Saud Medical City, Riyadh, SAU.
Aortoenteric fistula (AEF) is an abnormal connection between the aorta and the adjacent gastrointestinal (GI) tract and is often misdiagnosed in clinical practice. We present the case of a 65-year-old male, who presented with upper GI bleeding and melena. The patient underwent upper and lower GI examinations with no conclusive findings.
View Article and Find Full Text PDFA Case of Problem-Free Survival Five Years After Abdominal Aortic Sigmoid Colon Fistula Surgery.
Cureus
December 2024
Cardiovascular Surgery, Sapporo Medical University, Sapporo, JPN.
An a (AEF) is a rare but life-threatening condition where an abnormal connection forms between the aorta and the gastrointestinal tract, most commonly the duodenum. It can be primary (arising spontaneously due to an aortic aneurysm or infection) or secondary (complicating prior vascular surgery). Immediate recognition and surgical intervention are critical to manage severe gastrointestinal bleeding and prevent fatal outcomes.
View Article and Find Full Text PDFThoracic Endovascular Aortic Repair For The Management of Aorto-Esophageal Fistulae: A Systematic Review.
J Endovasc Ther
November 2024
Cardiac Surgery Unit, Cardiocentro Ticino Institute, EOC, Lugano, Switzerland.
Objective: Aorto-esophageal fistula (AEF) is a rare condition consisting in a fistula between the aorta and the esophagus. The thoracic endovascular aortic repair (TEVAR) has become an accepted treatment for initial AEF management, but large series are not available and outcomes are questionable. This study aims at evaluating the current evidence of TEVAR in AEF.
View Article and Find Full Text PDFClinical Characteristics and Early Surgical Outcomes of Aortoesophageal Fistula.
Ann Thorac Surg
October 2024
Department of Cardiovascular Surgery, Tokyo Medical University, Tokyo, Japan. Electronic address:
Article Synopsis
- A study analyzing the surgical treatment of aortoesophageal fistula (AEF) from 2020 to 2021 in Japan revealed that 61% of cases were secondary AEF, often arising from previous aortic surgeries.
- Among 123 patients, the operative mortality rate was 18.7%, with significant factors contributing to mortality including postoperative complications like bleeding, stroke, and pneumonia.
- The findings highlight the need for improved treatment strategies for AEF, as both surgical methods (open repair and TEVAR) were linked to high mortality rates and specific risk factors like dyslipidemia.
An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
CNS Drugs
November 2024
Chief Medical Officer and Senior Vice President of Research and Development, Supernus Pharmaceuticals, Inc, 9715 Key West Avenue, Rockville, MD, USA.
Background And Objective: Viloxazine ER (extended-release capsules; Qelbree) is a nonstimulant medication that has been approved by the United States Food and Drug Administration (FDA) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children (> 6 years old) and adults. This phase 3 open-label extension to a pivotal phase 3, double-blind trial evaluated the long-term safety and continued efficacy of viloxazine ER in adults with ADHD.
Methods: This was a multicenter, flexible-dose, open-label extension to a phase III, double-blind, placebo-controlled trial (NCT04016779).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!